Robert B Bazemore bought stock once, on Mar 30, 2021

Robert B. Bazemore is a lead independent director at Nuvation Bio Inc., where he serves on the board and its audit and compensation committees, reflecting his governance role as a seasoned corporate insider in the biopharmaceutical sector.( He has spent over 30 years in the development and commercialization of novel medicines, including serving as President, Chief Executive Officer, and director of Epizyme, Inc. from 2015 to 2021, during which he led the development and launch of the oncology therapy TAZVERIK for patients with follicular lymphoma and sarcoma.( Bazemore’s board service also includes directorships at Ardelyx, Inc. (since 2016), Akari Therapeutics Plc (appointed in 2024), and prior roles on the boards of Neon Therapeutics and BioNTech US, as well as chairing Pennsylvania BIO.(

Earlier in his career, Bazemore held senior leadership positions at Johnson & Johnson, including President of Janssen Biotech, where he oversaw successful U.S. launches of oncology therapies such as ZYTIGA and IBRUVICA and guided the company’s global immunology portfolio strategy.( He previously served as Chief Operating Officer of Synageva BioPharma Corp., helping build its global commercial and medical organization and supporting its transition through acquisition by Alexion Pharmaceuticals.( Bazemore holds a B.S. in Biochemistry from the University of Georgia, providing the scientific foundation for his extensive work in life sciences.( He continues to be active in the industry as a consultant and multi-company director, including his recent equity-based compensation transactions as a director and insider at Nuvation Bio Inc.(

Written by Perplexity from public sources.